![]() |
|
|
Vol. 288, Issue 3, 1151-1159, March 1999
Central Nervous System Preclinical Research (P.S., R.M.,
C.C., M.A.C., M.G.F., E.L.),
Department of Chemistry (P.P., M.V.),
Pharmacia & Upjohn S.p.A. Nerviano (MI), Italy;
Department of
Pharmacology and Toxicology (G.A.S., H.S.W., H.H.W.), National
Institutes of Health-National Institute of Neurological Disorders and
Stroke Anticonvulsant Screening Project, University of Utah, Salt Lake
City, Utah;
Department of General Physiology and Biochemistry (L.F.,
M.M., E.M.), University of Milano, Milan, Italy;
Department of
Neuroscience, Istituti Clinici di Perfezionamento (R.G. F.),
Milan, Italy; and
Department of Neurology, T. Jefferson University
(R.G.F.), Philadelphia, Pennsylvania
PNU-151774E
[(S)-(+)-2-(4-(3-fluorobenzyloxy)benzylamino)propanamide
methanesulfonate], a new anticonvulsant that displays a wide
therapeutic window, has a potency comparable or superior to that of
most classic anticonvulsants. PNU-151774E is chemically unrelated to
current antiepileptics. In animal seizure models it possesses a broad
spectrum of action. In the present study, the action mechanism of
PNU-151774E has been investigated using electrophysiological and
biochemical assays. Binding studies performed with rat brain membranes
show that PNU-151774E has high affinity for binding site 2 of the
sodium channel receptor, which is greater than that of phenytoin or
lamotrigine (IC50, 8 µM versus 47 and 185 µM,
respectively). PNU-151774E reduces sustained repetitive firing in a
use-dependent manner without modifying the first action potential in
hippocampal cultured neurons. In the same preparation PNU-151774E
inhibits tetrodotoxin-sensitive fast sodium currents and high
voltage-activated calcium currents under voltage-clamp conditions.
These electrophysiological activities of PNU-151774E correlate with its
ability to inhibit veratrine and KCl-induced glutamate release in rat
hippocampal slices (IC50, 56.4 and 185.5 µM,
respectively) and calcium inward currents in mouse cortical neurons. On
the other hand, PNU-151774E does not affect whole-cell
-aminobutryic
acid- and glutamate-induced currents in cultured mouse cortical
neurons. These results suggest that PNU-151774E exerts its
anticonvulsant activity, at least in part, through inhibition of sodium
and calcium channels, stabilizing neuronal membrane excitability and
inhibiting transmitter release. The possible relevance of these
pharmacological properties to its antiepileptic potential is discussed.
This article has been cited by other articles:
![]() |
D. R. Riddall, M. J. Leach, and J. Garthwaite A Novel Drug Binding Site on Voltage-Gated Sodium Channels in Rat Brain Mol. Pharmacol., January 1, 2006; 69(1): 278 - 287. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Smith and R. S. Obach SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING Drug Metab. Dispos., October 1, 2005; 33(10): 1409 - 1417. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Stocchi, G. Arnold, M. Onofrj, H. Kwiecinski, A. Szczudlik, A. Thomas, U. Bonuccelli, A. Van Dijk, C. Cattaneo, P. Sala, et al. Improvement of motor function in early Parkinson disease by safinamide Neurology, August 24, 2004; 63(4): 746 - 748. [Abstract] [Full Text] [PDF] |
||||